January 26, 2017 (New York) – International law firm Proskauer advised Solid Biosciences Inc. in raising $125 million in its Initial Public Offering. The company sold 7,812,500 shares of common stock at $16 per share. The shares are listed on the Nasdaq Global Select Market under the ticker symbol SLDB. J.P. Morgan, Goldman Sachs & Co. LLC and Leerink Partners acted as joint book-running managers for the IPO.
Solid Biosciences is a Cambridge, Massachusetts-based life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). The company will use the net proceeds from the IPO primarily to fund research and development expenses, including to advance its lead gene transfer product candidate, SGT-001, through Phase I/II clinical trial activities.
The Proskauer team was led by partner Julie Allen and included senior counsel Daniel Forman and law clerk Janice Lee (Corporate); partners Arnold May and Malcolm Hochenberg and associate Yomarie Habenicht (Tax); partner Ali Fawaz and associate Cristopher Jones (Employee Benefits & Executive Compensation).
Proskauer’s Global Capital Markets Group includes more than 60 lawyers across the U.S., Europe and Latin America. We have been recognized by the Financial Times for “Innovation in the Business of Law” for our groundbreaking IPO and Global High-Yield Bond studies. Recent matters on which the Firm has advised include representing Floor & Décor Holdings, Inc. in its $192 million IPO on the New York Stock Exchange; The Carlyle Group (TCG) BDC, Inc. in its $166 million IPO on the Nasdaq Global Select Market; and Citigroup and J.P. Morgan as book-running managers in connection with the $294 million IPO of Five Point Holdings, LLC on the New York Stock Exchange.